Sun Pharmaceutical Industries Limited

NSE: SUNPHARMA

Pharma Pharmaceuticals

₹1,793

+0.37%EOD · 11 Jun

Sun Pharmaceutical Industries Limited is a listed Pharmaceuticals company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹4.29 L Cr

52W Range

₹1917 / ₹1548

Volume

489K

1Y Return

+7.5%

P/E Ratio

37.3

P/B Ratio

5.1

ROE

14.7%

Debt / Equity

5.52

Peers in Pharma

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Sun Pharmaceutical Industries Limited(this stock)	₹1,793	₹4.29 L Cr	37.3	5.1	14.7%	0.93%
Cipla LimitedCIPLA	₹1,383.3	₹1.11 L Cr	29.2	3.4	11.7%	0.93%
Dr. Reddy's Laboratories LimitedDRREDDY	₹1,276.9	₹1.06 L Cr	24.9	2.8	11.8%	0.63%
Lupin LimitedLUPIN	₹2,255.8	₹1.03 L Cr	19.5	4.6	26.9%	0.53%

Technical Indicators

Full analysis · objective math, not advice

Returns

+0.4%

+0.6%

-5.9%

+2.0%

+3.2%

+7.5%

Weinstein Stage

Stage 2 — Advancing (uptrend)

RSI (14)

26 Oversold

Trend Template

6/7strong

Moving Averages (price vs MA)

20-DMA

₹1815

below

50-DMA

₹1786

above

150-DMA

₹1755

above

200-DMA

₹1735

above

From 52W High

-6.4%

From 52W Low

+15.8%

Support (20D)

₹1757

Resistance (20D)

₹1903

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+9.0% CAGR

Up 7 of last 11 years

Earnings Quality

Fully cash-backed

OCF / Net Profit = 2.48x · 7/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.